Modified anti-CD19 T-cell therapy (Fred Hutchinson Cancer Research Center)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameModified anti-CD19 T-cell therapy (Fred Hutchinson Cancer Research Center)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesFred Hutchinson Cancer Research Center

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesFred Hutchinson Cancer Research Center

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A